Benzinga

MARCH 13, 2023

Provention Bio Inc (NASDAQ: PRVB ) shares are rocketing higher Monday after Sanofi (NASDAQ: SNY ) announced plans to acquire the biopharmaceutical company. Sanofi has its eyes set on TZIELD, Provention Bio's diabetes therapy, which was approved in the U.S. Full story available on Benzinga.com

Equity 52

Equity 52

Law 360 M&A

MARCH 13, 2023

Sanofi SA, led by Weil Gotshal & Manges LLP, will acquire New Jersey-based pharmaceutical company Provention Bio Inc., billion in equity, according to an announcement by both companies Monday. advised by Ropes & Gray LLP, in a deal worth $2.9

Equity 40

Equity 40

Law 360 M&A

APRIL 4, 2023

A Provention Bio Inc. investor has filed a lawsuit seeking to delay the biopharmaceutical company's pending $2.9

Equity 40

Equity 40

Reynolds Holding

MARCH 27, 2023

We examine developments in federal securities litigation involving special purpose acquisition companies. This figure is significantly lower than in 2016, when the Delaware Court of Chancery effectively put an end to the practice of disclosure-only settlements in In re Trulia Inc. Stockholder Litigation , 29 A.3d 3d 884 (Del.

Technology 59

Technology Start-ups Compliance Finance 59